SMITH PATRICK F
Known title: PRESIDENT, INTEGRATED DRUG DEVCIK: 0001890360
Associated companies
Transaction History
| CERT | ▼ Sell | Open Market | 5,409 | $60K | 10/7/2024 | View on chart |
| CERT | ▲ Buy | Option Exercise | 7,151 | $0 | 10/4/2024 | View on chart |
| CERT | ▼ Sell | Tax Withholding | 1,742 | $19K | 10/4/2024 | View on chart |
| CERT | ▼ Sell | Open Market | 649 | $12K | 4/2/2024 | View on chart |
| CERT | ▼ Sell | Open Market | 3,024 | $51K | 4/2/2024 | View on chart |
| CERT | ▼ Sell | Open Market | 328 | $6K | 4/2/2024 | View on chart |
| CERT | ▼ Sell | Open Market | 4,740 | $79K | 4/2/2024 | View on chart |
| CERT | ▼ Sell | Open Market | 5,264 | $88K | 4/2/2024 | View on chart |
| CERT | ▼ Sell | Open Market | 422 | $7K | 4/2/2024 | View on chart |
| CERT | ▼ Sell | Tax Withholding | 1,532 | $27K | 4/1/2024 | View on chart |
| CERT | ▲ Buy | Option Exercise | 8,646 | $0 | 4/1/2024 | View on chart |
| CERT | ▼ Sell | Tax Withholding | 2,733 | $49K | 4/1/2024 | View on chart |
| CERT | ▼ Sell | Tax Withholding | 2,690 | $48K | 4/1/2024 | View on chart |
| CERT | ▲ Buy | Option Exercise | 7,852 | $0 | 4/1/2024 | View on chart |
| CERT | ▼ Sell | Open Market | 5,000 | $90K | 2/20/2024 | View on chart |
| CERT | ▼ Sell | Open Market | 19,104 | $412K | 6/5/2023 | View on chart |
| CERT | ▼ Sell | Tax Withholding | 2,894 | $69K | 3/31/2023 | View on chart |
| CERT | ▼ Sell | Tax Withholding | 1,532 | $36K | 3/31/2023 | View on chart |
| CERT | ▲ Buy | Option Exercise | 8,646 | $0 | 3/31/2023 | View on chart |
| CERT | ▼ Sell | Open Market | 2,387 | $32K | 11/9/2022 | View on chart |
| CERT | ▼ Sell | Tax Withholding | 1,244 | $15K | 11/1/2022 | View on chart |
| CERT | ▼ Sell | Open Market | 10,000 | $177K | 8/16/2022 | View on chart |
| CERT | ▼ Sell | Open Market | 10,000 | $192K | 6/8/2022 | View on chart |
| CERT | ▼ Sell | Open Market | 3,352 | $75K | 4/4/2022 | View on chart |
| CERT | ▼ Sell | Tax Withholding | 1,532 | $33K | 4/1/2022 | View on chart |
| CERT | ▲ Buy | Grant | 3,631 | $0 | 11/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Certara analysts raise price targets, maintain positive outlook
TD Cowen kept its buy rating on Certara and lifted its price target to $11. Barclays also maintained an equal‑weight stance and increased its target to $9. A Yahoo analysis noted the company's fair‑value estimate moving higher as the turnaround gains traction. The upgrades suggest growing confidence among analysts.
Certara analysts raise price targets, maintain positive outlook. TD Cowen kept its buy rating on Certara and lifted its price target to $11. Barclays also maintained an equal‑weight stance and increased its target to $9. A Yahoo analysis noted the company's fair‑value estimate moving higher as the turnaround gains traction. The upgrades suggest growing confidence among analysts.